198 related articles for article (PubMed ID: 29328476)
41. β-Elemene inhibits the metastasis of B16F10 melanoma cells by downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9.
Shi H; Liu L; Liu L; Geng J; Zhou Y; Chen L
Melanoma Res; 2014 Apr; 24(2):99-107. PubMed ID: 24535052
[TBL] [Abstract][Full Text] [Related]
42. uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo.
Kargiotis O; Chetty C; Gogineni V; Gondi CS; Pulukuri SM; Kyritsis AP; Gujrati M; Klopfenstein JD; Dinh DH; Rao JS
Int J Oncol; 2008 Nov; 33(5):937-47. PubMed ID: 18949356
[TBL] [Abstract][Full Text] [Related]
43. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways.
Schnaper HW; Barnathan ES; Mazar A; Maheshwari S; Ellis S; Cortez SL; Baricos WH; Kleinman HK
J Cell Physiol; 1995 Oct; 165(1):107-18. PubMed ID: 7559792
[TBL] [Abstract][Full Text] [Related]
44. The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells.
Iwamoto J; Mizokami Y; Takahashi K; Matsuoka T; Matsuzaki Y
Helicobacter; 2008 Jun; 13(3):174-82. PubMed ID: 18466392
[TBL] [Abstract][Full Text] [Related]
45. Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding.
Dupont DM; Madsen JB; Hartmann RK; Tavitian B; Ducongé F; Kjems J; Andreasen PA
RNA; 2010 Dec; 16(12):2360-9. PubMed ID: 20962041
[TBL] [Abstract][Full Text] [Related]
46. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
47. uPA and uPAR contribute to NK cell invasion through the extracellular matrix.
Al-Atrash G; Kitson RP; Xue Y; Mazar AP; Kim MH; Goldfarb RH
Anticancer Res; 2001; 21(3B):1697-704. PubMed ID: 11497249
[TBL] [Abstract][Full Text] [Related]
48. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
49. Urokinase plasminogen activator system as a potential target for cancer therapy.
Mekkawy AH; Morris DL; Pourgholami MH
Future Oncol; 2009 Nov; 5(9):1487-99. PubMed ID: 19903074
[TBL] [Abstract][Full Text] [Related]
50. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
51. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system.
Ertongur S; Lang S; Mack B; Wosikowski K; Muehlenweg B; Gires O
Int J Cancer; 2004 Jul; 110(6):815-24. PubMed ID: 15170662
[TBL] [Abstract][Full Text] [Related]
53. Urokinase Type Plasminogen Activator and the Molecular Mechanisms of its Regulation in Cancer.
Santibanez JF
Protein Pept Lett; 2017; 24(10):936-946. PubMed ID: 28820062
[TBL] [Abstract][Full Text] [Related]
54. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
55. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
[TBL] [Abstract][Full Text] [Related]
56. Detection of matrix metalloproteinases (MMP), tissue inhibitor of metalloproteinase-2, urokinase and plasminogen activator inhibitor-1 within matrigel and growth factor-reduced matrigel basement membrane.
Gillette KM; Forbes K; Sehgal I
Tumori; 2003; 89(4):421-5. PubMed ID: 14606648
[TBL] [Abstract][Full Text] [Related]
57. Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta.
Shiou SR; Datta PK; Dhawan P; Law BK; Yingling JM; Dixon DA; Beauchamp RD
J Biol Chem; 2006 Nov; 281(45):33971-81. PubMed ID: 16959768
[TBL] [Abstract][Full Text] [Related]
58. MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.
Mori Y; Akita K; Tanida S; Ishida A; Toda M; Inoue M; Yashiro M; Sawada T; Hirakawa K; Nakada H
J Biol Chem; 2014 Dec; 289(51):35193-204. PubMed ID: 25371209
[TBL] [Abstract][Full Text] [Related]
59. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Hudson MA; McReynolds LM
J Natl Cancer Inst; 1997 May; 89(10):709-17. PubMed ID: 9168186
[TBL] [Abstract][Full Text] [Related]
60.
Rasouli BS; Ghadimi-Darsajini A; Nekouian R; Iragian GR
J Cancer Res Ther; 2017; 13(2):246-251. PubMed ID: 28643742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
